Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives (Q38018679)

27 August 2017

title

Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives (English)

1 reference

27 August 2017

1 reference

Kallirroi I. Kalantzi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22697863

3 January 2025

Maria E. Tsoumani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22697863

3 January 2025

Ioannis A. Goudevenos

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22697863

3 January 2025

Alexandros D. Tselepis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22697863

3 January 2025

language of work or name

English

0 references

publication date

1 May 2012

1 reference

27 August 2017

May 2012

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22697863

full work available at URL

3 January 2025

http://www.future-drugs.com/doi/abs/10.1586/ecp.12.19

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22697863

http://www.tandfonline.com/doi/pdf/10.1586/ecp.12.19

3 January 2025

1 reference

Expert Review of Clinical Pharmacology

3 January 2025

published in

1 reference

27 August 2017

volume

5

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

319-336

1 reference

Platelet activation and atherothrombosis

27 August 2017

cites work

1 reference

Cell adhesion mechanisms in platelets

21 January 2018

1 reference

Antiplatelet agents for the treatment and prevention of atherothrombosis

21 January 2018

1 reference

Antiplatelet therapies for the treatment of cardiovascular disease

21 January 2018

1 reference

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

21 January 2018

1 reference

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation

21 January 2018

1 reference

The genetics of antiplatelet drug resistance

21 January 2018

1 reference

Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers.

21 January 2018

1 reference

Gastrointestinal safety of triflusal solution in healthy volunteers: a proof of concept endoscopic study

21 January 2018

1 reference

Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial

21 January 2018

1 reference

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis

21 January 2018

1 reference

P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.

21 January 2018

1 reference

Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.

21 January 2018

1 reference

Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting

21 January 2018

1 reference

A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE st

21 January 2018

1 reference

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance".

21 January 2018

1 reference

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease

21 January 2018

1 reference

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

21 January 2018

1 reference

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

21 January 2018

1 reference

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patien

21 January 2018

1 reference

Clopidogrel with or without omeprazole in coronary artery disease

21 January 2018

1 reference

Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function — a flow cytometry study

21 January 2018

1 reference

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.

21 January 2018

1 reference

Clopidogrel–Drug Interactions

21 January 2018

1 reference

Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial

21 January 2018

1 reference

Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects

21 January 2018

1 reference

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

21 January 2018

1 reference

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

21 January 2018

1 reference

Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.

21 January 2018

1 reference

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

Advances in antiplatelet therapy: agents in clinical development

21 January 2018

1 reference

Intravenous platelet blockade with cangrelor during PCI.

21 January 2018

1 reference

Platelet inhibition with cangrelor in patients undergoing PCI.

21 January 2018

1 reference

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Ear

21 January 2018

1 reference

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percuta

21 January 2018

1 reference

The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients

21 January 2018

1 reference

Effect of synthetic peptides corresponding to residues 313-332 of the alphaIIb subunit on platelet activation and fibrinogen binding to alphaIIbbeta3.

21 January 2018

1 reference

Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy

21 January 2018

1 reference

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

21 January 2018

1 reference

Novel agents for anti-platelet therapy

21 January 2018

1 reference

21 January 2018

1 reference

Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates

21 January 2018

1 reference

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

21 January 2018

1 reference

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

21 January 2018

1 reference

Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis.

21 January 2018

1 reference

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

21 January 2018

1 reference

Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials

21 January 2018

1 reference

The pharmacology of cilostazol

21 January 2018

1 reference

Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in

21 January 2018

1 reference

Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Pati

21 January 2018

1 reference

Secondary prevention of stroke: can we do better than aspirin?

21 January 2018

1 reference

Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy

21 January 2018

1 reference

Protease-activated receptors: contribution to physiology and disease

21 January 2018

1 reference

Protease-activated receptors in hemostasis, thrombosis and vascular biology

21 January 2018

1 reference

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

21 January 2018

1 reference

Mechanism of action and clinical development of platelet thrombin receptor antagonists.

21 January 2018

1 reference

Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease

21 January 2018

1 reference

Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions

21 January 2018

1 reference

Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome

21 January 2018

1 reference

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

21 January 2018

1 reference

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

21 January 2018

1 reference

Antiplatelet therapy: thrombin receptor antagonists

21 January 2018

1 reference

Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial

21 January 2018

1 reference

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

21 January 2018

1 reference

Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial

21 January 2018

1 reference

TP receptor antagonism: a new concept in atherothrombosis and stroke prevention

21 January 2018

1 reference

Thromboxane and the thromboxane receptor in cardiovascular disease

21 January 2018

1 reference

The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies.

21 January 2018

1 reference

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients

21 January 2018

1 reference

von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes.

21 January 2018

1 reference

GPVI and alpha2beta1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys

21 January 2018

1 reference

A consensus tetrapeptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal anti-VWF antibody that inhibits the von Willebrand factor-collagen interaction

21 January 2018

1 reference

First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers

21 January 2018

1 reference

Discovery and development of therapeutic aptamers.

21 January 2018

1 reference

Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779.

21 January 2018

1 reference

Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha.

21 January 2018

1 reference

Engineering and characterization of a chimeric anti-platelet glycoprotein Ibalpha monoclonal antibody and preparation of its Fab fragment

21 January 2018

1 reference

GPVI levels in platelets: relationship to platelet function at high shear

21 January 2018

1 reference

The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats

21 January 2018

1 reference

Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody

21 January 2018

1 reference

Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy

21 January 2018

1 reference

Vorapaxar in the secondary prevention of atherothrombotic events

21 January 2018

1 reference

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-

21 January 2018

1 reference

Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis

21 January 2018

3

1 reference

Plasma kallikrein and thrombin are cleared through unrelated hepatic pathways

3 January 2025

10

1 reference

Simvastatin administration reduces thromboxane production in subjects taking aspirin: Links between aspirin resistance and thrombin generation

3 January 2025

11

1 reference

Aspirin resistance and platelet turnover: A 25-year old issue

3 January 2025

13

1 reference

Influence of high‐density lipoprotein and paraoxonase‐1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy

3 January 2025

24

1 reference

Paraoxonase-1 is a major determinant of clopidogrel efficacy

3 January 2025

25

1 reference

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting

3 January 2025

26

1 reference

The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment

3 January 2025

27

1 reference

A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days

3 January 2025

29

1 reference

Clopidogrel differentially affects platelet‐mediated thrombosis and inflammatory response in patients with acute coronary syndromes

3 January 2025

37

1 reference

Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies

3 January 2025

42

1 reference

Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy

3 January 2025

43

1 reference

ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and

3 January 2025

45

1 reference

Pharmacokinetics and the antiplatelet effect of a new clopidogrel formulation, clopidogrel besylate, in healthy subjects.

3 January 2025

53

1 reference

Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate

3 January 2025

55

1 reference

Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping

3 January 2025

58

1 reference

From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis

3 January 2025

60

1 reference

Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect

3 January 2025

66

1 reference

Localization of a site interacting with human platelet receptor on carboxy-terminal segment of human fibrinogen γ chain

3 January 2025

75

1 reference

Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms

3 January 2025

79

1 reference

Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo

3 January 2025

84

1 reference

Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials

3 January 2025

94

1 reference

Thrombin functions during tissue factor-induced blood coagulation

3 January 2025

96

1 reference

Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists

3 January 2025

100

1 reference

Thrombin and protease-activated receptors (PARs) in atherothrombosis.

3 January 2025

110

1 reference

Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage

3 January 2025

111

1 reference

Prostanoid and TP-receptors in atherothrombosis: Is there a role for their antagonism?

3 January 2025

116

1 reference

Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis

3 January 2025

119

1 reference

A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis

3 January 2025

120

1 reference

Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis

3 January 2025

133

1 reference

3 January 2025

Identifiers

DOI

10.1586/ECP.12.19

1 reference

27 August 2017

1 reference